Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY27 Earnings Presentation
19 slides from Morepen Laboratories's earnings presentation, Aug 4, 2026
Slide 1: Exchange filing cover letter: Investor Presentation Q1 FY27
IAOmEtt ~ Yoonrnf r, • !,., Excellence ~ Date: 04/08/2026 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presen
Slide 2: Building Today. Transforming Tomorrow.
JlOREPEN 'The]'!)' OJ growing 'Tog~ Building Today. Transforming Tomorrow. Q1'FY27 Investor Presentation Advancing Chemistry. Creating Possibilities. Discovery. Development. Delivery. 1
Slide 3: Q1 FY27 — A Quarter of Commercial Validation
JlOREPEN Q1 FY27 — A Quarter of Commercial Validation 'The]'!)' OJ growing 'Tog~ Rs. 575 Cr 3x EBITDA Rs. 825 Cr Highest Ever Quarterly Highest Ever Quarterly CDMO mandate enters Revenue EBITDA- 3x YoY commercial supplies 15%+ EBITDA Export +111% Medical Devices Blended EBITDA Prioritisation of Main
Slide 4: Financial Performance Reflects Operating Leverage (YoY)
JlOREPEN 'The]'!)' OJ growing 'Tog~ Financial Performance Reflects Operating Leverage (YoY) +34% +34% +207% +207% +394% +394% Rs. 575.31 Cr Rs. 87.72 Cr Rs. 56.35 Cr Revenue EBITDA PAT 15%+ 31% 19% EBITDA Margin API Growth Devices Growth Rs. 58 Cr Commercial CDMO Dispatches Performance driven by ope
Slide 5: From Commodity APIs to Innovation-led Manufacturing
JlOREPEN From Commodity APIs to Innovation-led Manufacturing 'The]'!)' OJ growing 'Tog~ Quarterly Transaction- Volatile ► Old Commodity Commodity based API business pricing volatility earnings Morepen business Recurring Scalable New Addition Innovation-led Long-duration customer Predictable operatin
Slide 6: The CDMO Journey Has Entered Commercial Scale
JlOREPEN 'The]'!)' OJ growing 'Tog~ The CDMO Journey Has Entered Commercial Scale Development Customer ► Validation Order Commercial Commercial Audit Received Production Dispatched Why This Is More Than Just One Order ► Long-duration customer programme ► Recurring revenues ► Higher margins ► Global
Slide 7: Operating Leverage Begins
Operating Leverage Begins JlOREPEN 'The]'!)' OJ growing 'Tog~ Rs. in Crores, except margin Q1'FY26 429.64 Revenue Q1'FY27 575.31 +34% 100 200 300 400 500 600 0 Q1'FY26 28.58 EBITDA +207% Q1'FY27 87.72 0 20 40 60 80 100 +111% Q1'FY26 6.65% Export Revenue EBITDA Margin 2.3X Q1'FY27 15.25% 0 5 10 15 20
Slide 8: API Business Returns to Healthy Profitability
JlOREPEN API Business Returns to Healthy Profitability 'The]'!)' OJ growing 'Tog~ Core API franchise stabilising while CDMO becomes the next growth layer. 31% API Growth API Export Up 42% Healthy recovery in the base Better product mix with customer business priortisation Improved Profitability Capa
Slide 9: Regulatory Track Record
JlOREPEN 'The]'!)' o_J growing 'Tog~ Regulatory Track Record **** * d *EU-GMP* 7 •, " **•* * ANVISA CHINANMPA Quality Global audit GMP-compliant systems readiness manufacturing supporting CDMO scale-up Nil 483 Observations — 4 USFDA inspections in a row Quality credibility is a core enabler of long-
Slide 10: Building The Next Phase of Growth
11:iiii a........._ JlOREPEN 'The]'!)' OJ growing 'Tog~ Building The Next Phase of Growth Capacity Augmentation Global Partnerships Scaling Capacity to Meet Built for Global Pharmaceutical Global Demand Partnerships PA Capability Scaleup Global Compliance Innovation & Technology Roadmap Responsible
Slide 11: Scaling Capacity to Meet Global Demand
JlOREPE~I qJ 'Ibe Jl!)' growing 'Togejg_ FY30 Phase-4 1200 KL Expansion Scaling Capacity to Meet Global Demand Phase-3 FY29 Expansion 1000 1000 KL KL Q2-FY28 Phase-2 800 800 KL KL Expansion Phase-1 Q2-FY27 Expansion 600 600 KL KL Q4-FY26 535 535 KL KL Expanding manufacturing capacity to support larg
Slide 12: Built for Global Pharmaceutical Partnerships
JlOREPEN Built for Global Pharmaceutical Partnerships 'The]'!)' OJ growing 'Tog~ , "II r "'II Global Quality & & ESG & & Sustainability ,_ Regulatory Systems - to. .... to. ...,; , ~ , "II Global Supply Network Morepen Process & & R&D Expertise ... ...,; to. .... I r- ' "II - , "II Reliable Reliable
Slide 13: Innovation & Technology Roadmap
Innovation & JlOREPEN Technology Roadmap 'The]'!)' OJ growing 'Tog~ Future Direction: • New Technologies & Innovations • Selective, Capability-Led Expansion Emerging: Oligos & New Modalities Specialty APIs Difficult-to-Make Molecules Next: • CComplex omplex Chemistry • Advanced Intermediates Today:
Slide 14: Responsible Manufacturing for Global Partnerships
JlOREPEN 'The]'!)' OJ growing 'Tog~ Responsible Manufacturing for Global Partnerships , "' , "' Global Compliance: Sustainable Operations: • GMP GMP systems • Zero Zero Liquid Discharge • Customer audits • Solar initiatives • Regulatory discipline • Cleaner manufacturing \.. ~ \... ~ r r "' " Busine
Slide 15: 14
14
Slide 16: Medical Devices: A Scalable Healthcare Platform
Medical Devices: A Scalable Healthcare Platform JlOREPEN 'The]'!)' OJ growing 'Tog~ High-growth chronic-care platform with recurring consumables revenue. Blood Glucose Meter Blood Pressure Monitor 20 Mn installed base Strong brand presence + 500 Mn strips per annum distribution reach Consumables Eng
Slide 17: Investment Highlights
JlOREPEN Investment Highlights 'The]'!)' OJ growing 'Tog~ Commercial validation, operating leverage and multiple growth engines. Rs. 825 Cr Rs. 58 Cr Rs. 575 Cr EBITDA CDMO mandate Commercial Highest-ever EBITDA up 3x YoY; entered commercial dispatches completed quarterly revenue margin at 15%+ supp
Slide 18: Outlook: Building the Next Phase of Growth
JlOREPEN Outlook: Building the Next Phase of Growth 'The]'!)' OJ growing 'Tog~ Commercial execution, capacity expansion and platform depth to drive the next phase. Near Term Medium Term Long Term • Commercial CDMO supplies • Capacity augmentation • Innovation-led manufacturing • API profitability re
Slide 19: Safe Harbour Statement
Safe Harbour Statement This presentation has been prepared by Morepen Laboratories Limited (“Morepen” or the “Company”) for informational purposes only and does not constitute an offer, invitation, recommendation, or solicitation to purchase or subscribe to any securities. Certain statements contain